Publication
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Journal Paper/Review - Aug 8, 2013
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Electronic
Pages
Brief description/objective
BACKGROUND
Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).
METHODS
Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.
RESULTS
Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.
CONCLUSION
Abiraterone has important antitumour activity in men with CRPC even after DES exposure.